SCHEMBL10332014

SCHEMBL10332014

CCc1ccc(-c2ccc(C(=O)N(C)C)c(Cl)c2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 4/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
NPC1 O15118 3/20 0.51
ATR Q13535 1/20 0.47
MTOR P42345 3/20 0.43
CCNE1 P24864 1/20 0.43
CDK2 P24941 1/20 0.43
TP53 P04637 2/20 0.43
PDK2 Q15119 1/20 0.42
MAP4K1 Q92918 3/20 0.41
CECR2 Q9BXF3 1/20 0.41
CTSA P10619 1/20 0.40
CYP3A4 P08684 2/20 0.39
ABL1 P00519 1/20 0.39
GPR119 Q8TDV5 2/20 0.39
PIK3CA P42336 2/20 0.39
P2RX7 Q99572 1/20 0.39
NFKB1 P19838 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10331377 0.80 ATR (0.47) RAB9ANPC1ATRMTORCCNE1
SCHEMBL4475971 0.79 ALDH1A1 (0.47) RAB9ASMN1; SMN2NPC1TP53PDK2
SCHEMBL10332007 0.79 SMN1; SMN2 (0.71) RAB9ASMN1; SMN2NPC1ATRTP53
SCHEMBL2056331 0.74 GRM2 (0.55) RAB9ASMN1; SMN2NPC1TP53ABL1
SCHEMBL30032697 0.72 ALDH1A1 (0.51) RAB9ASMN1; SMN2NPC1ATRMTOR
SCHEMBL18058386 0.71 KMO (0.67)
SCHEMBL13874374 0.71 ALDH1A1 (0.41) RAB9ASMN1; SMN2NPC1TP53CYP3A4
SCHEMBL14145447 0.71 KMT2A (0.35) RAB9ASMN1; SMN2NPC1MTORTP53
SCHEMBL12377894 0.70 RAB9A (0.58) RAB9ASMN1; SMN2NPC1TP53NFKB1
SCHEMBL12603839 0.70 SMN1; SMN2 (0.61) RAB9ASMN1; SMN2NPC1TP53ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8222247-B2 Modulators of glucocorticoid receptor, AP-1, and/or NF-kappabeta activity and use thereof BRISTOL-MYERS SQUIBB COMPANY (US) 2012-07-17 US disclosed
US-20100004219-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF BRISTOL-MYERS SQUIBB COMPANY 2010-01-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100004219-A1 MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-KAPPABETA ACTIVITY AND USE THEREOF NR3C1, NFRKB, RELA RAB9A 1283/4885SMN1; SMN2 3208/4885NPC1 1816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.